HistoSonics, , the manufacturer of the non-invasive Edison® Histotripsy System, announced a patient from the University of Rochester Medical Cent...
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development...
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT&t...
SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD...
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coa...
This investment opportunity offers a unique chance for individuals and institutions to actively participate in the growth and transformation of the healthc...
Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands1. Among these, primary open-angl...
Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation ...
"We're excited to work with Rutgers Cancer Institute in their efforts to optimize therapeutic strategies for patients with early-stage breast cancer," said...
Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases....
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System,announced it has entered into a collabo...
Series A led by Sofinnova Partners and OMX Ventures Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a ...
Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with ...
Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inh...
© 2025 Biopharma Boardroom. All Rights Reserved.
